Cimetropium bromide

Cimetropium bromide
Cimetropium_bromide.png
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Cimetropium bromide is a pharmaceutical drug classified as an antimuscarinic agent. It is primarily used in the management of gastrointestinal disorders, particularly those involving spasms of the smooth muscle in the gastrointestinal tract.

Pharmacology

Cimetropium bromide functions by blocking the action of acetylcholine on muscarinic receptors located on the smooth muscle cells of the gastrointestinal tract. This action leads to a reduction in muscle spasms and provides relief from pain and discomfort associated with conditions such as irritable bowel syndrome and spastic colon.

Mechanism of Action

The drug acts as a competitive antagonist at muscarinic receptors, which are a subtype of acetylcholine receptors. By inhibiting these receptors, cimetropium bromide decreases the motility and tone of the smooth muscles in the gastrointestinal tract, thereby alleviating symptoms of cramping and spasms.

Clinical Use

Cimetropium bromide is indicated for the treatment of various gastrointestinal conditions characterized by hypermotility and spasm. It is often prescribed for patients suffering from irritable bowel syndrome (IBS), where it helps to manage symptoms such as abdominal pain and discomfort.

Side Effects

As with other antimuscarinic agents, cimetropium bromide may cause side effects such as dry mouth, blurred vision, constipation, and urinary retention. These effects are due to the systemic anticholinergic activity of the drug.

Administration

Cimetropium bromide is typically administered orally in the form of tablets. The dosage and frequency depend on the severity of the condition being treated and the patient's response to the medication.

Related pages

• Antimuscarinic
• Irritable bowel syndrome
• Acetylcholine receptor